New Info on Clot Risk Added to Contraceptive Labels

The labels of 11 drospirenone-containing oral contraceptives are getting an update to reflect an increased risk of blood clots associated with the drugs. A review of recent epidemiologic studies showed as high as a three-fold increase in the risk of blood clots with these products when compared with contraceptives containing levonorgestrel or other progestins, the FDA said. This data will now be included in the labeling, which will note that other epidemiological studies found no additional risk of blood clots.
Washington Drug Letter